Eligibility and safety
Weight loss tablet eligibility and safety in the UK
Eligibility depends on the medicine, your BMI, your medical history, and whether a prescriber thinks the route is appropriate. This page is a practical overview, not a substitute for a clinical assessment.
The short version
- Orlistat, Mysimba, Rybelsus and newer oral GLP-1 routes do not use the same prescribing rules.
- Pregnancy, planned pregnancy and breastfeeding always need a clinician-led discussion before any weight-loss medicine is used.
- Mysimba is not a GLP-1 medicine.
- Rybelsus is a type 2 diabetes medicine in the UK, even though it is often searched as part of the wider oral semaglutide conversation.
General eligibility checks
BMI and treatment goal
Private providers usually assess BMI, weight-related conditions, and whether you have already tried diet, activity, or another medicine.
Medical history
The prescriber will usually ask about pancreatitis, gallbladder disease, seizure history, blood pressure, thyroid history, and current medicines.
Current medicines
Interactions matter. Mysimba in particular needs a careful medicines review, while orlistat can affect absorption of some medicines and fat-soluble vitamins.
Monitoring
Some routes need ongoing reviews, side-effect monitoring, dose checks, or blood-pressure follow-up rather than a one-off order.
Orlistat eligibility and caution points
Orlistat is usually the most straightforward tablet route to discuss because it is a long-established non-GLP-1 option. Even so, it is not suitable for everyone.
- Typical route: adult patients who meet the provider’s BMI criteria and do not have obvious contraindications.
- Use caution with: malabsorption problems, cholestasis, and medicine combinations where fat absorption changes matter.
- Pregnancy and breastfeeding: do not assume it is a routine or “safe” route. This needs clinician advice.
- What to expect: diet and side-effect counselling matters because the medicine works differently from the appetite-suppressing routes.
Mysimba eligibility and caution points
Mysimba is a tablet combination of naltrexone and bupropion. It is not a GLP-1 medicine, and the screening questions are different from the GLP-1 routes.
- Use caution with: uncontrolled high blood pressure, seizure history, eating disorders, bipolar disorder, and medicines that raise interaction risk.
- Monitoring: blood pressure and tolerability matter early in treatment.
- Pregnancy: Mysimba should not be treated as a routine option in pregnancy or when pregnancy is being planned.
GLP-1 routes and oral semaglutide questions
Tablet search intent often mixes together Rybelsus, Wegovy pill, future oral GLP-1 medicines and older tablet routes. They need to be kept separate.
| Medicine or route | UK role | Main caution |
|---|---|---|
| Rybelsus | Oral semaglutide licensed for type 2 diabetes | Do not treat it as a general UK weight-loss tablet route |
| Wegovy pill | Weight-management tablet approval story and provider-availability check | Approval does not automatically mean stock, prescribing or NHS access |
| Future oral GLP-1 medicines | Pipeline and watchlist category | Do not assume UK access until a named route is live |
Pregnancy, breastfeeding and specialist advice
If you are pregnant, planning pregnancy, breastfeeding, or have a complex medical history, the safe route is a direct clinical discussion before you compare prices or providers. This is one of the clearest lines in the whole category.
Read the pregnancy and tablet safety notes in this eligibility and safety hub if that is the part you need to check first.
What to check next
Once you know which medicine family you are actually comparing, it is much easier to judge the right provider, the right caution points, and whether a route is even live in the UK.
Eligibility and safety
Use the treatment clusters to keep safety checks grounded in the right medicine type
Eligibility questions change depending on whether someone is looking at Orlistat, Mysimba or a GLP-1 tablet route.